NewsRoom Articles - Page 46 of 46 - PsychedelicNewsWire (PNW)

TuesdayMay 09, 2017 3:23 pm

ChineseInvestors.com, Inc. (CIIX) Aims to Excel in CBD Markets

For nearly two decades, ChineseInvestors.com (OTCQB: CIIX) has delivered a wide range of products, information, and services, including several subscription-based services, for the global Chinese speaking population. The specialized investment services company provides real-time market commentary, analysis, and education-related information in the Chinese language, as well as offering consultation, advertising, and public relations services. The company’s product diversity is a result of its growth-focused, long term quest for value-add opportunities. Not satisfied with a 100,000+ user base, a recognizable 18-year-old brand, and a target market in excess of two billion Chinese speaking people, ChineseInvestors.com recently executed a first-to-market milestone by…

MondayMay 08, 2017 12:55 pm

India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals

A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies (http://nnw.fm/u3xAh). According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research. Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad…

FridayMay 05, 2017 2:37 pm

India Globalization Capital, Inc. (NYSE: IGC) Engages a Critical Point in Cannabis History

Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies. Cannabis’ history doesn’t begin in the 1960s. Scientists have dated burned cannabis seeds found in Siberia to 3,000 B.C., and mummified psychoactive marijuana has been found in tombs of individuals buried around 2,500 B.C. Fast forward a few thousand years and add laws, regulations, and cultural stigma, and behold one of the most disputed substances. In the 1850s, recreational cannabis was considered fashionable in the U.S., and it was…

MondayApr 10, 2017 9:13 am

InMed Pharmaceuticals, Inc. (IMLFF) Offers More than Just a Non-THC Cannabinoid Drug Pipeline

Now that 28 states have passed comprehensive medical marijuana laws, conditions have never looked better for expanding research and development (R&D) into the therapeutic benefits of cannabinoids, which is exactly what InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is doing. Its efforts have already borne results: the company has two novel drug candidates in its pipeline. But there’s more to InMed than meets the eye; the Vancouver, Canada-based company has developed a proprietary process to manufacture cannabinoids based on biosynthesis. In addition, it has constructed an algorithm to identify the cannabinoids most likely to have beneficial therapeutic effect. With this…

FridayApr 07, 2017 9:21 am

India Globalization Capital, Inc. (NYSE: IGC) at the Forefront of Innovation Thanks to Strategic Alliances

How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions? In the case of India Globalization Capital, Inc. (NYSE MKT: IGC), the answer is creative management’s ability to identify opportunity, coupled with a relentless drive toward innovation. IGC made its switch to the marijuana industry after its CEO, Executive Chairman, and President Ram Mukunda was unafraid to recognize and act on a need for the company to make a positive and swift switch to a stronger and more lucrative market.…

ThursdayMar 30, 2017 8:30 am

Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players

Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief. Leading specialty pharma companies such as India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Cara Therapeutics, Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), and INSYS Therapeutics, Inc. (NASDAQ: INSY) are tirelessly working to expand combination therapeutics product lines, while Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) developing an opioid alternative drug intended to reduce pain after surgery. To date, it is estimated that the annual national cost of…

WednesdayMar 29, 2017 11:41 am

ChineseInvestors.com, Inc. (CIIX) Executes a First to Market Milestone

A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. ChineseInvestors.com (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population. The company provides real-time market commentary, analysis, and education-related services in the Chinese language and offers several types of subscription-based services. Headquartered in Los Angeles with offices in New York City and Shanghai, the company also offers consultation services to private companies seeking to go public, as well as advertising and public relations services. Seizing opportunity, this diverse…

ThursdayMar 16, 2017 1:58 pm

ChineseInvestors.com (CIIX) Helping Treat Patients with Amyotrophic Lateral Sclerosis

Late February, a study was released (http://nnw.fm/R2CEp) reviewing evidence that supports the use of cannabinoids to treat Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others. Currently, ALS is treated with riluzole, a drug that controls neuronal signaling, but this drug does not cure the disease and can only slightly increase the chance of survival. With more effective therapeutic options…

ThursdayDec 08, 2016 11:00 am

Vitality Biopharma (VBIO) Starts Presentation at LD Micro Main Event

Vitality Biopharma (OTCQB: VBIO) is focused on leveraging the power of cannabinoids to treat serious neurological and inflammatory disorders. The company has developed a new class of cannabinoid prodrugs (cannabosides), which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.…

WednesdayAug 31, 2016 4:26 pm

With Hemp-based Drinks, Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (LB6A.F) is Strongly Rooted in Functional Beverages Market

If you plan to visit Laguna Beach in Orange County, California, to attend the Food & Wine Pairing Dinner on September 1, 2016, you may not be aware that the area is associated with culinary delights other than vino. Located midway between Los Angeles and San Diego, and stretching for over seven miles, Laguna Beach has lent its name to Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (LB6A.F), a network marketing company with products based on the nutritional health benefits derived from hemp. Just like wine, the consumption of hemp beverages is still an avant-garde pursuit. Nevertheless, its management team…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050